Thick-wall cavity predicts worse progression-free survival in lung adenocarcinoma treated with first-line EGFR-TKIs
Số trang: 9
Loại file: pdf
Dung lượng: 2.52 MB
Lượt xem: 5
Lượt tải: 0
Xem trước 2 trang đầu tiên của tài liệu này:
Thông tin tài liệu:
Cavity occurs in 5.7 to 14.9% of patients with lung adenocarcinoma (ADC). However, the impact of cavity on the therapeutic response to epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) in ADC patients with EGFR mutations remains unclear.
Nội dung trích xuất từ tài liệu:
Thick-wall cavity predicts worse progression-free survival in lung adenocarcinoma treated with first-line EGFR-TKIs
Nội dung trích xuất từ tài liệu:
Thick-wall cavity predicts worse progression-free survival in lung adenocarcinoma treated with first-line EGFR-TKIs
Tìm kiếm theo từ khóa liên quan:
BMC Cancer Cavitary ADC Adenocarcinoma treated Epidermal growth factor receptor Tyrosine kinase inhibitorsGợi ý tài liệu liên quan:
-
Differences between physician and patient preferences for cancer treatments: A systematic review
13 trang 167 0 0 -
6 trang 166 0 0
-
Immune checkpoint inhibitors and their impact on liver enzymes and attenuation
7 trang 139 0 0 -
2011–2021 rising prevalence of HPV infection among oropharyngeal carcinoma in France
9 trang 109 0 0 -
12 trang 87 0 0
-
19 trang 72 0 0
-
17 trang 60 0 0
-
9 trang 35 0 0
-
11 trang 35 0 0
-
12 trang 33 0 0